BiomX (NYSEMKT:PHGE) Stock Price Down 1%

BiomX Inc. (NYSEMKT:PHGE) shares fell 1% during trading on Tuesday . The company traded as low as $1.00 and last traded at $1.01. 57,623 shares changed hands during trading, a decline of 16% from the average session volume of 68,601 shares. The stock had previously closed at $1.02.

Analyst Ratings Changes

Separately, HC Wainwright reaffirmed a “buy” rating and set a $2.00 price target on shares of BiomX in a research report on Friday, August 16th.

BiomX Trading Down 1.0 %

The firm has a market cap of $70.50 million, a price-to-earnings ratio of -1.66 and a beta of 1.30. The company has a fifty day moving average price of $0.66 and a 200-day moving average price of $0.46. The company has a current ratio of 2.84, a quick ratio of 2.84 and a debt-to-equity ratio of 0.51.

Hedge Funds Weigh In On BiomX

An institutional investor recently bought a new position in BiomX stock. Ikarian Capital LLC purchased a new position in BiomX Inc. (NYSEMKT:PHGE) in the first quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The institutional investor purchased 10,817,327 shares of the company’s stock, valued at approximately $4,868,000. Ikarian Capital LLC owned 19.59% of BiomX at the end of the most recent quarter. Institutional investors and hedge funds own 40.57% of the company’s stock.

BiomX Company Profile

BiomX Inc, a clinical-stage biopharmaceutical company, develops products using natural and engineered phage technologies designed to target and kill specific harmful bacteria associated with chronic disease. It is developing BX211, a phage therapy, which is in phase 2 clinical study for the treatment of diabetic foot osteomyelitis.